Taimur Sher
Overview
Explore the profile of Taimur Sher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
107
Citations
1696
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lyle M, Farina J, Wiedmeier-Nutor E, Lindpere V, Klanderman M, Nativi-Nicolau J, et al.
Clin Transplant
. 2025 Jan;
39(1):e70070.
PMID: 39775986
Background: The prognosis in patients with advanced cardiac amyloidosis (CA) remains poor. Objectives: We sought to describe survival post heart transplantation (HT) in amyloid compared with non-amyloid recipients, highlight waitlist...
2.
Niazi Z, Sher T
Mayo Clin Proc Innov Qual Outcomes
. 2024 Dec;
8(6):549-550.
PMID: 39735708
No abstract available.
3.
Ailawadhi S, Adu Y, Frank R, Das S, Hodge D, Fernandez A, et al.
Blood Cancer J
. 2024 May;
14(1):86.
PMID: 38806475
Multiple myeloma (MM) therapeutics have evolved tremendously in recent years, with significant improvement in patient outcomes. As newer treatment options are developed, stem cell transplant (SCT) remains an important modality...
4.
Parrondo R, Dutta N, LaPlant B, Elliott J, Fernandez A, Zimmerman A, et al.
Br J Haematol
. 2024 Jan;
204(5):1825-1829.
PMID: 38286472
This phase II study evaluated time-limited (24 cycles) treatment with ibrutinib and ixazomib in newly diagnosed (NDWM; n = 9) and relapsed/refractory (RRWM; n = 12) Waldenström macroglobulinaemia (WM). The...
5.
Das S, Ailawadhi S, Sher T, Roy V, Fernandez A, Parrondo R
Curr Oncol
. 2023 Nov;
30(11):9627-9633.
PMID: 37999117
While immunotherapies, such as CAR T therapy and bi-specific antibodies, have revolutionized the treatment of multiple myeloma (MM), patients with AL amyloidosis have been excluded from trials with these agents...
6.
Ailawadhi S, Ailawadhi M, Dutta N, Parrondo R, Roy V, Sher T, et al.
Cancer Med
. 2023 Aug;
12(18):19013-19020.
PMID: 37587868
Introduction: Health information technology (HIT) has the potential to improve healthcare delivery and engagement. Studying racial-ethnic disparities in HIT engagement will help understand and overcome challenges to healthcare utilization. Methods:...
7.
Yadav U, Kumar S, Baughn L, Dispenzieri A, Greipp P, Ketterling R, et al.
Blood
. 2023 Jul;
142(22):1871-1878.
PMID: 37494698
Most patients with solitary bone plasmacytomas (SBP) progress to multiple myeloma (MM) after definitive radiation therapy as their primary treatment. Whether the presence of high-risk (HR) cytogenetic abnormalities by fluorescence...
8.
Yassine F, Kharfan-Dabaja M, Tsalantsanis A, Roy V, Zubair A, Murthy H, et al.
Bone Marrow Transplant
. 2023 Jul;
58(10):1130-1136.
PMID: 37479753
Due to the advent of effective novel therapies for multiple myeloma (MM), the use of cryopreserved autologous peripheral blood hematopoietic cells (APBHC) for a salvage autologous transplant (auto-HCT) is in...
9.
Aslam F, Manochakian R, Lou Y, Colon-Otero G, Sher T
Cancer Rep (Hoboken)
. 2023 Jul;
6 Suppl 1:e1856.
PMID: 37421166
Background: Clinical trials are an essential part of advancing care for cancer patients. Historically, however, racial minorities and females have been underrepresented in these trials. Efforts like the National Institute...
10.
Alhaj Moustafa M, Parrondo R, Abdulazeez M, Roy V, Sher T, Alegria V, et al.
Anticancer Drugs
. 2023 Apr;
35(1):63-69.
PMID: 37067996
Daratumumab is an anti-CD38 mAb, used frequently in combination with lenalidomide and pomalidomide. No studies compared daratumumab plus lenalidomide and dexamethasone (DRd) to daratumumab plus pomalidomide and dexamethasone (DPd) in...